Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Cancer|December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.Cancer Discovery|November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.Nature Communications|May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trialPadmanee Sharma, Michael Krainer, Fred Saad, et al.The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.Nature Communications|March 10, 2026
Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastomaJongHoon Ha, Yifan Wang, Yifan Ma, et al.Pageof 6